Summary
Absolute proof of efficacy can only be given by placebo controlled trials. It is, however, important to classify a drug within the spectrum of existing therapeutic alternatives and, where effective treatment is available, it may be imperative due to ethical considerations to demonstrate that one drug is as effective as another.
The issue of therapeutic equivalence trials is discussed along the lines of the important items which should be defined in the protocol: a) the target parameter, which is the primary endpoint of the trial, b) the reference drug, which should be selected with respect to efficacy (superior to others), and safety (largest amount of data), c) the acceptance range, which depends on the primary endpoint, and its implication for the clinical endpoints of morbidity and mortality (the conventional acceptance range for bioequivalence trials does not apply), and d) the statistical procedures, which must take into consideration the unsuitability of the conventional power approach for confirming equivalence.
In an equivalence trial, compared to those that are placebo-controlled, the proof that one drug is as effective as another relies much more upon the quality of conduct of the study according to Good Clinical Practice.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Allen ME, Vandenburg MJ (1991) Rules, regulations and their impact on the investigator. Br J Clin Pharmacol 32: 463–465
Bardhan KD, Saul DM, Balmforth GV, Maruyama T, Duthie HL, Fussey IV, Heading RC, Fettes M, Logan RFA, Holdsworth CD, Langman MJ, Dronfield MW, Larkworthy W, Smith PM, Edwards JL, Wyllie JH, Haggie SJ, Hawkins BW (1977) The effect of cimetidine on duodenal ulceration. In: Burland WL, Simkins MA (eds) Cimetidine. Proceedings of the 2nd International Symposium on histamine-H2-receptor antagonists. Excerpta Medica, Amsterdam Oxford
Binder HJ, Manousos ON, Peter P, Porro PG, Semb LS, Wyllie J quoted by Chuong JJH, Spiro HM (1982) Cimetidine and duodenal ulcer. An analysis of methodologic problems in randomized controlled trials. J Clin Gastroenterol 4: 311–320
Blum AL, Siewert JR, Halter F (1978) Ulkustherapie mit Cimetidin. Dtsche Med Wochenschr 103: 135–139
Bonnevie O (1978) Survival in peptic ulcer. Gastroenterology 75: 1055–1060
Chow SC, Shao J (1990) An alternative approach for the assessment of bioequivalence between two formulations of a drug. Biometrical J 32: 969–976
Chuong JJH, Spiro HM (1982) Cimetidine and duodenal ulcer: an analysis of methodologic problems in randomized clinical trials. J Clin Gastroenterol 4: 311–320
Cloud ML (1987) Safety of nizatidine in clinical trials conducted in the USA and Europe. Scand J Gastroenterol 22 [Suppl 136]: 29–36
Collen MJ, Hanan MR, Maher JA, Rent M, Stubrin SE, Arguello JF, Gardner L (1980) Cimetidine vs placebo in duodenal ulcer therapy. Dig Dis Sci 25: 744–749
Daly LE (1991) Confidence intervals and sample sizes: don't throw out all your old sample size tables. Br Med J 302: 333–336
Farrington CP, Manning G (1990) Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero-risk-difference or non-unity-relative-risk. Stat Med 9: 1447–1454
Feldman M, Burton ME (1990) Histamine2-receptor-antagonists. N Engl J Med 323: 1749–1755
Gardner MJ, Altman DG (1989) Statistics with confidence. The Universities Press, Belfast
Gillespie G, Gray GR, Smith S, Mackenzie I, Crean GP (1977) Short term and maintenance cimetidine treatment in severe duodenal ulceration. In: Burland WL, Simkins MA (eds) Cimetidine. Proceedings of the 2nd International Sympossium on histamine-H2-receptor antagonists. Excerpta Medica, Amsterdam Oxford
Gould AL (1991) Another view of active-controlled trials. Control Clin Trials 12: 474–485
Greenland S (1988) On sample-size and power calculations for studies using confidence intervals. Am J Epidemiol 128: 231–237
Gudjonsson B, Spiro HM (1978) Response to placebos in ulcer disease. Am J Med 65: 399–402
Hauschke D, Steinijans VW (1990) A distribution-free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharm Toxicol 28: 72–80
Havu N (1986) Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion 35 [Suppl 1]: 42–55
Langman MJS (1986) Towards estimation and confidence intervals (editorial). Br Med J 292: 716
Leber PD (1989) Hazards of inference: the active control investigation. Epilepsia 30 [Suppl 1]: 57–63
McHugh RB, Le CT (1984) Confidence estimation and the size of a clinical trial. Control Clin Trials 5: 157–163
Makuch R, Johnson M (1989) Issues in planning and interpreting active controlled equivalence trials. J Clin Epidemiol 42: 503–511
Malchow H, Sewing KF, Albinus M, Horn B, Schomerus H, Dölle W (1978) Cimetidin in der stationären Behandlung des peptischen Ulkus. Dtsch Med Wochenschr 103: 149–154
Morice A (1992) Good clinical practice and the clinical pharmacologist. Br J Clin Pharmacol 32: 529–530
Moss S, Calam J (1992) Helicobacter pylori and peptic ulcers: the present position. Gut 33: 289–292
Price AH, Brogden RN (1988) Nizatidine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, its therapeutic use in peptic ulcer disease. Drugs 36: 521–539
Schiller LR et al (1986) Ulcer complications during short-term therapy of duodenal ulcer with active agents and placebo. Gastroenterology 90: 478–481
Schuriman DJ (1987) A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 15: 657–680
Sheiner LB (1991) The intellectual health of clinical drug evaluation. Clin Pharmacol Ther 50: 4–9
Westlake WJ (1988) Bioavailability and bioequivalence of pharmaceutical formulations. In: Peace K (ed) Biopharmaceutical statistics for drug development. Dekker, New York Basel
Wittes J, Lakatos E (1989) Surrogate endpoints in clinical trials: cardiovascular diseases. Stat Med 8: 415–425
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Garbe, E., Röhmel, J. & Gundert-Remy, U. Clinical and statistical issues in therapeutic equivalence trials. Eur J Clin Pharmacol 45, 1–7 (1993). https://doi.org/10.1007/BF00315342
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00315342